Altimmune
ALTClinical Pipeline
Program / Asset
Target Indications
Development Phase
Financial Statements & Analysis
Total Gross Revenue
$0.01M $0.01M $0.04M —
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
($17.24M) ($14.96M) ($66.43M) ($16.19M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($5.69M) ($5.90M) ($28.10M) ($8.05M)
Operating Income / (Loss)
($22.92M) ($20.86M) ($94.49M) ($24.24M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
$1.13M $2.43M $7.54M $2.90M
Interest & Debt Servicing Expense
($0.26M) ($0.49M) ($1.64M) ($1.07M)
Other Non-Operating Income / (Expense)
$0.78M $1.84M $5.71M $1.68M
Income Tax Provision / (Benefit)
($0.68M) ($0.68M) ($0.68M) —
NET INCOME / (NET LOSS)
($22.15M) ($19.01M) ($88.09M) ($22.56M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$183.1M$61.2M$43.8M$97.6M
Short-Term Marketable Investments
// --$149.5M$229.7M$233.9M
Total Liquid Cash Resources
$183.1M$210.8M$273.5M$331.5M
Accounts Receivable, Net
// --// --// --// --
Prepaid Expenses & Other Current Assets
$4.4M$4.4M$3.0M$1.4M
Total Current Assets
$188.4M$216.6M$278.2M$334.7M
Property, Plant and Equipment, Net
$0.4M$0.3M$0.3M$0.2M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$190.3M$218.4M$279.9M$335.6M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
$0.9M$4.8M$2.7M$1.5M
Accrued Expenses & Clinical Liabilities
$1.8M$2.4M$4.7M$2.6M
Total Current Liabilities
$9.2M$12.6M$15.0M$11.3M
Long-Term Corporate Debt Balances
$14.3M$14.4M$34.3M$34.5M
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$5.4M$5.8M$5.8M$5.8M
Total Liabilities Block
$29.0M$32.8M$55.0M$51.6M
Total Stockholders' Equity
$161.4M$185.6M$224.9M$284.0M
TOTAL LIABILITIES & EQUITY
$190.3M$218.4M$279.9M$335.6M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
20.44x 17.18x 18.55x 29.56x
R&D Expenditure Flow
$33.1M$48.0M$66.4M$16.2M
Net Income / (Loss)
($22.15M) ($19.01M) ($88.09M) ($22.56M)
Depreciation & Amortization
$0.06M $0.09M $0.11M $0.02M
Stock-Based Compensation
$7.58M $11.13M $16.08M $3.38M
Change in Accounts Receivable
($0.22M) $0.30M $0.68M $0.45M
Change in Prepaid Assets / Expenses
$1.90M $1.90M $0.20M ($1.62M)
Change in Payables & Clinical Accruals
$0.64M $4.59M $2.51M ($1.19M)
Other Operating Source / (Use) Changes
($24.00M) ($47.09M) $0.98M $0.58M
Net Cash from Operating Activities
($36.19M) ($48.09M) ($67.53M) ($20.94M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
($0.01M) ($0.01M) ($0.01M) ($0.02M)
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
— — — —
Net Cash from Investing Activities
$96.01M ($53.31M) ($132.47M) ($3.69M)
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
$15.00M $15.00M $35.00M —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
$72.57M $112.09M $173.73M $8.74M
Net Cash from Financing Activities
$86.36M $125.71M $206.84M $78.47M
NET CONSOLIDATED CHANGE IN CASH
$146.18M $24.31M $6.83M $53.84M